Neuroblastoma

Adrian Van Der Kleij; Peter Sminia

doi:10.1007/1-4020-4448-8-23

Neuroblastoma

Adrian Van Der Kleij, Peter Sminia

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic › peer-review

Abstract

Hypoxia is recognized as a major cause of failure of radiotherapy. In clinical oncology, several treatment modalities have been applied to overcome tumour hypoxia either by increasing the oxygen delivery to tumour cells (ie carbogen and hyperbaric oxygen) or by combined treatment with oxygen mimicking agents to sensitize hypoxic cells (ie misonidazole). Radiation enhancement by HBO in the treatment of patients with recurrent Neuroblastoma stage IV in a setting of unsealed source radionuclide brachytherapy seems to be the most promising indication of that approach

Original language	English
Title of host publication	Handbook on Hyperbaric Medicine
Publisher	Springer Netherlands
Pages	469-475
Number of pages	7
ISBN (Electronic)	9781402044489
ISBN (Print)	1402043767, 9781402043765
DOIs	https://doi.org/10.1007/1-4020-4448-8-23
Publication status	Published - 1 Jan 2006

Access to Document

10.1007/1-4020-4448-8-23

Cite this

@inbook{2bef9fe2bfc94816953c819bc2a5342d,

title = "Neuroblastoma",

abstract = "Hypoxia is recognized as a major cause of failure of radiotherapy. In clinical oncology, several treatment modalities have been applied to overcome tumour hypoxia either by increasing the oxygen delivery to tumour cells (ie carbogen and hyperbaric oxygen) or by combined treatment with oxygen mimicking agents to sensitize hypoxic cells (ie misonidazole). Radiation enhancement by HBO in the treatment of patients with recurrent Neuroblastoma stage IV in a setting of unsealed source radionuclide brachytherapy seems to be the most promising indication of that approach",

keywords = "Neuroblastoma, Oxygen free radicals, Oxygen sensitizer, Tumour hypoxia",

author = "{Van Der Kleij}, Adrian and Peter Sminia",

year = "2006",

month = jan,

day = "1",

doi = "10.1007/1-4020-4448-8-23",

language = "English",

isbn = "1402043767",

pages = "469--475",

booktitle = "Handbook on Hyperbaric Medicine",

publisher = "Springer Netherlands",

address = "Netherlands",

}

TY - CHAP

T1 - Neuroblastoma

AU - Van Der Kleij, Adrian

AU - Sminia, Peter

PY - 2006/1/1

Y1 - 2006/1/1

N2 - Hypoxia is recognized as a major cause of failure of radiotherapy. In clinical oncology, several treatment modalities have been applied to overcome tumour hypoxia either by increasing the oxygen delivery to tumour cells (ie carbogen and hyperbaric oxygen) or by combined treatment with oxygen mimicking agents to sensitize hypoxic cells (ie misonidazole). Radiation enhancement by HBO in the treatment of patients with recurrent Neuroblastoma stage IV in a setting of unsealed source radionuclide brachytherapy seems to be the most promising indication of that approach

AB - Hypoxia is recognized as a major cause of failure of radiotherapy. In clinical oncology, several treatment modalities have been applied to overcome tumour hypoxia either by increasing the oxygen delivery to tumour cells (ie carbogen and hyperbaric oxygen) or by combined treatment with oxygen mimicking agents to sensitize hypoxic cells (ie misonidazole). Radiation enhancement by HBO in the treatment of patients with recurrent Neuroblastoma stage IV in a setting of unsealed source radionuclide brachytherapy seems to be the most promising indication of that approach

KW - Neuroblastoma

KW - Oxygen free radicals

KW - Oxygen sensitizer

KW - Tumour hypoxia

UR - http://www.scopus.com/inward/record.url?scp=84920163141&partnerID=8YFLogxK

U2 - 10.1007/1-4020-4448-8-23

DO - 10.1007/1-4020-4448-8-23

M3 - Chapter

AN - SCOPUS:84920163141

SN - 1402043767

SN - 9781402043765

SP - 469

EP - 475

BT - Handbook on Hyperbaric Medicine

PB - Springer Netherlands

ER -

Neuroblastoma

Abstract

Access to Document

Other files and links

Cite this